Efficient gene delivery by EGF-lipoplexes in vitro and in vivo

Nanomedicine

Volumn 6, Issue 1, 2011, Pages 89-98

  Buñuales, Mara ^a   Düzgüne, Nejat ^b   Zalba, Sara ^a   Garrido, Mara J ^a   Tros De Ilarduya, Conchita ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

EGF; gene delivery; lipoplexes; liposomes; nanotechnology; pharmaceutical technology; targeted nanoparticles

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; CHOLESTEROL; DEOXYRIBONUCLEASE I; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 12; LIPOPLEX; LUCIFERASE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENDOCYTOSIS; GENE DELIVERY SYSTEM; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NANOMEDICINE; NONHUMAN; PLASMID; PRIORITY JOURNAL; SURFACE CHARGE;

ANIMALS; CELL LINE, TUMOR; DEOXYRIBONUCLEASES; DNA; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENETIC VECTORS; HUMANS; INTERLEUKIN-12; LIPOSOMES; MICE; MICE, INBRED BALB C; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFECTION; UP-REGULATION;

EID: 78650630537     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.100     Document Type: Article

References (35)

1. Jolly D: Viral vector systems for gene therapy. Cancer Gene Ther. 1, 51-64 (1994).
2. Yang Y, Nunes FA, Berencsi K et al.: Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl Acad. Sci. USA. 91, 4407-4411 (1994).
3. Thomas CE, Ehrhardt A, Kay MA: Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4(5), 346-358 (2003).
4. Merdan T, Kopecek J, Kissel T: Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv. Drug Deliv. Rev. 54(5), 715-758 (2002).
5. Tros De Ilarduya C, Düzgüne? N: Effcient gene transfer by transferrin lipoplexes in the presence of serum. Biochim. Biophys. Acta. 1463(2), 333-342 (2000).
6. Tros De Ilarduya C, Arangoa MA, Moreno-Aliaga MJ et al.: Enhanced gene delivery in vitro and in vivo by improved transferrin-lipoplexes. Biochim. Biophys. Acta. 1561(2), 209-221 (2002).
7. Arangoa MA, Düzgüne? N, Tros De Ilarduya C: Increased receptor-mediated gene delivery to the liver by protamine-enhanced-asialofetuin- lipoplexes. Gene Ther. 10(1), 5-14 (2003).
8. Wu J, Liu P, Zhu JL et al.: Increased liver uptake of liposomes and improved targeting effcacy by labeling with asialofetuin in rodents. Hepatology 27(3), 772-778 (1998).
9. Gottschalk S, Cristiano RJ, Smith LC et al.: Folate receptor mediated DNA delivery into tumor cells: potosomal disruption results in enhanced gene expression. Gene Ther. 1(3), 185-191 (1994).
10. Zhao XB, Lee RJ: Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor. Adv. Drug Deliv. Rev. 56(8), 1193-1204 (2004).
11. Yanagihara K, Cheng H, Cheng PW: Effects of epidermal growth factor, transferrin, and insulin on lipofection effciency in human lung carcinoma cells. Cancer Gene Ther. 7, 59-65 (2000).
12. Hwang SY, Cho do Y, Kim HK et al.: Preparation of targeting proteoliposome by postinsertion of a linker molecule conjugated with recombinant human epidermal growth factor. Bioconj. Chem. 21(2), 345-351 (2010).
13. Michael SI, Curiel DT: Strategies to achieve targeted gene approach for the development of improved synthetic delivery via the receptor-mediated endocytosis pathway. Gene Ther. 1(4), 223-232 (1994).
14. Baulida J, Kraus MH, Alimandi M et al.: All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J. Biol. Chem. 271, 5251-5257 (1996).
15. Kim H, Muller WJ: The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp. Cell Res. 253(1), 78-87 (1999).
16. Yang JL, Qu XJ, Russell PJ et al.: Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon a. Gut. 53(1), 123-129 (2004).
17. Singletary SE, Baker FL, Spitzer G et al.: Biological effect of epidermal growth factor on the in vitro growth of human tumors. Cancer Res. 47(2), 403-406 (1987).
18. Srivastava A, Alexander J, Lomakin I et al.: Immunohistochemical expression of transforming growth factor a and epidermal growth factor receptor in pancreatic endocrine tumors. Hum. Pathol. 32(11), 1184-1189 (2001).
19. Chou JL, Fan Z, DeBlasio T et al.: Constitutive overexpression of cyclin D1 in human breast epithelial cells does not prevent G1 arrest induced by deprivation of epidermal growth factor. Breast Cancer Res. Treat. 55(3), 267-283 (1999).
20. Lane HA, Beuvink I, Motoyama AB et al.: ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol. Cell Biol. 20(9), 3210-3223 (2000).
21. Herbst RS, Bunn PA Jr: Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin. Cancer Res. 9(16 Pt 1), 5813-5824 (2003).
22. Pollack VA, Savage DM, Baker DA et al.: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exp. Ther. 291(2), 739-748 (1999).
23. Sugawa N, Ueda S, Nakagawa Y et al.: An antisense EGFR oligodeoxynucleotide enveloped in lipofectin induces growth inhibition in human malignant gliomas in vitro. J. Neurooncol. 39(3), 237-244 (1998).
24. Song S, Liu D, Peng J et al.: Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int. J. Pharm. 363(1-2), 155-161 (2008).
25. Frederiksen KS, Abrahamsen N, Cristiano RJ et al.: Gene delivery by an epidermal growth factor/DNA polyplex to small cell lung cancer cell lines expressing low levels of epidermal growth factor receptor. Cancer Gene Ther. 7(2) 262-268 (2000).
26. Cristiano RJ, Roth JA: Epidermal growth factor mediated DNA delivery into lung cancer cells via the epidermal growth factor receptor. Cancer Gene Ther. 3(1), 4-10 (1996).
27. Liu X, Tian P, Ju D et al.: Systemic genetic transfer of p21 WAF-1 and GM-CSF utilizing of a novel oligopeptide-based EGF receptor targeting polyplex. Cancer Gene Ther. 10, 529-539 (2003).
28. Shiota M, Shamsur L, Kawahara S et al.: Improvement of targeted gene delivery to human cancer cells by a novel trifunctional crosslinker. Chem. Asian. J. 4(8), 1318-1322 (2009).
29. Wolschek M, Thallinger C, Kursa M et al.: Specifc systemic nonviral gene delivery to human hepatocellular carcinoma xenografts in SCID mice. Hepatology. 36(5), 1106-1114 (2002).
30. Kikuchi A, Sugaya S, Ueda H et al.: Effcient gene transfer to EGF receptor overexpressing cancer cells by means of EGF-labeled cationic liposomes. Biochem. Bioph. Res. Co. 227, 666-671 (1996).
31. Niidome T, Huang L: Gene therapy progress and prospects: nonviral vectors. Gene Ther. 9(24) 1647-1652 (2002).
32. Xu L, Huang CC, Huang, W et al.: Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol. Cancer Ther. 1, 337-346 (2002).
33. Anwer K, Kao G, Rolland A et al.: Peptide-mediated gene transfer of cationic lipid/plasmid DNA complexes to endothelial cells. J. Drug Target. 12, 215-221 (2004).
34. Rejman J, Oberle V, Zuhorn IS et al.: Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem. J. 377, 159-169 (2004).
35. Ourlin JC, Vilarem MJ, Daujat M et al.: Lipid-mediated transfection of normal adult human hepatocytes in primary culture. Anal. Biochem. 247, 34-44 (1997).